BiotechTube
Home/Lutris Pharma/John Paul Waymack, M.D., Sc.D.
JP

John Paul Waymack, M.D., Sc.D.

Director, Regulatory Affairs

Lutris Pharma

Therapeutic Areas

Oncology

Lutris Pharma Pipeline

DrugIndicationPhase
LUT014EGFR inhibitor‑induced acneiform lesions in metastatic colorectal cancerPhase 2

Leadership Team at Lutris Pharma

SR
Sumant Ramachandra, M.D., Ph.D., MBA
Chief Executive Officer and Board Director
CJ
Colleen Johnson, M.S, DABT
Director, Pre‑Clinical Development
LM
Laura Millichamp, Ph.D.
Director, Chemistry Manufacturing Control
View full Lutris Pharma profile